Treatment for Uremic Itching
Begin with optimizing dialysis adequacy (Kt/V ~1.6), correcting metabolic abnormalities (calcium-phosphate balance, parathyroid hormone, anemia with erythropoietin), and applying emollients for xerosis before advancing to pharmacologic therapy. 1
Stepwise Treatment Algorithm
First-Line: Foundational Management
Before initiating specific antipruritic medications, address these modifiable factors:
- Optimize dialysis adequacy: Target Kt/V around 1.6; consider high-flux hemodialysis over standard haemodialysis filtration 1
- Correct metabolic derangements: Normalize calcium-phosphate balance and control parathyroid hormone to accepted levels 1
- Treat anemia: Use erythropoietin as indicated 1
- Apply emollients liberally: Essential for managing xerosis (dry skin), which lowers the itch threshold even if not the primary cause 1
Second-Line: Phototherapy (Strongest Evidence)
BB-UVB (broadband ultraviolet B) phototherapy is the most effective treatment with the highest strength of recommendation (Grade A) for many patients with uremic pruritus. 1 This modulates immune response and reduces inflammation.
Third-Line: Systemic Pharmacotherapy
When foundational measures and phototherapy are insufficient or unavailable, consider these options in order:
Gabapentin (most robust evidence among widely available medications):
- Dose: 100-300 mg post-dialysis, three times weekly 1
- Evidence: Multiple placebo-controlled trials showing >50% reduction in visual analogue scores 1
- Critical caveat: These are much lower doses than used in non-ESRD populations; use cautiously and monitor for drowsiness 1
- Also improves associated depression and sleep disturbances 1
Alternative systemic options (all Grade D recommendations):
- Capsaicin cream 0.025%: Apply four times daily; depletes substance P in peripheral sensory neurons. In one crossover trial, 14/17 patients reported marked relief with effects lasting up to 8 weeks after cessation 1
- Topical calcipotriol: Consider as alternative topical agent 1
What NOT to Use
Avoid these medications:
- Cetirizine: Specifically shown to be ineffective in uremic pruritus 1
- Long-term sedating antihistamines: May predispose to dementia and should be avoided except in palliative care settings (Grade B recommendation) 1
Emerging and Alternative Therapies
Complementary approaches (Grade D):
- Auricular acupressure or aromatherapy may be considered 1
- Activated charcoal showed significant improvement in one RCT 1
Novel agents (from recent research):
- Difelikefalin: κ-opioid receptor agonist showing effective symptomatic relief in the KALM-1 trial 2, 3
- Nalfurafine: Another opioid-based therapy with notable symptom relief 3
- Sertraline: May provide benefit but has delayed onset 3
Definitive Treatment
Renal transplantation is the only definitive cure (Grade D recommendation). 1
Critical Clinical Pitfalls
No single treatment is universally effective - the evidence consistently shows that no one topical or systemic strategy works for all patients 1
Dosing errors with gabapentin: Clinicians accustomed to standard gabapentin dosing (often 300-3600 mg daily in non-renal patients) must remember that dialysis patients require only 100-300 mg three times weekly post-dialysis 1
Antihistamine misconception: Despite being commonly prescribed, antihistamines have minimal evidence in uremic pruritus, and sedating ones carry dementia risk 1
Overlooking dialysis optimization: Pruritus is more common in underdialysed patients; increasing dialysis adequacy should precede pharmacologic escalation 1
Evidence Quality Considerations
The 2018 British Association of Dermatologists guidelines [1-1 provide the most comprehensive and recent guideline-level evidence. The KDIGO 2015 consensus 4 emphasizes that symptom management requires a stepwise approach with nonpharmacological interventions first, then advancing to complex therapies. Most treatment recommendations carry Grade D strength (expert opinion/case series) except for BB-UVB phototherapy (Grade A) and the recommendation against long-term sedating antihistamines (Grade B) 1.
Recent research 5, 6, 2, 3 highlights emerging therapies like difelikefalin and nalfurafine, though these are not yet widely available and await incorporation into formal guidelines.